Skip to main content

01.12.2017 | Study protocol | Ausgabe 1/2017 Open Access

BMC Cancer 1/2017

TUmor-volume to breast-volume RAtio for improving COSmetic results in breast cancer patients (TURACOS); a randomized controlled trial

BMC Cancer > Ausgabe 1/2017
M. Lagendijk, E. L. Vos, A. H. J. Koning, M. G. M. Hunink, J. P. Pignol, E. M. L. Corten, C. de Monye, C. H. M. van Deurzen, J. H. van Dam, W. W. Vrijland, C. M. E. Contant, C. Verhoef, W. van Lankeren, L. B. Koppert
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12885-017-3280-y) contains supplementary material, which is available to authorized users.
Automated Breast Volume Scanner
Breast Conserving Surgery
Breast Cancer Conservative Treatment. cosmetic result
Breast Retraction Assessment
Data Safety Monitoring Board
European Organisation of Research and Treatment of Cancer quality of life questionnaire
EQ-5D-5 L
Euro-QoL-5D-5 L
Quality-Adjusted Life Years
Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer


For early stage breast cancer patients the goal of therapy is to ensure both local control and breast preservation with an optimal cosmetic outcome. The current standard of care is breast-conserving surgery (BCS) followed by adjuvant whole breast irradiation [ 13]. Large randomised clinical trials in the 80’s have shown that this treatment is equivalent, in terms of overall and breast-cancer specific survival, to a mastectomy [ 4]. The frequency of BCS performed is estimated at an annual rate of 60% in the Netherlands [ 5]. Oncoplastic surgery, an operation performed jointly by a plastic surgeon and a breast-cancer surgeon specialist, is currently more frequently performed with the goal of obtaining the best cosmetic outcome possible. At time of diagnosis, however, the treatment decision whether to perform a mastectomy (with or without a breast reconstruction) or BCS is often subjective. Unfavourable cosmetic outcome following BCS is significantly associated with decreased quality of life and psychosocial functioning [ 6, 7]. Poor cosmetic outcome following BCS is reported in up to 30% of breast cancer patients [ 811]. Pre-operative knowledge of the expected cosmetic outcome would thus be a welcome treatment decision aid.
As previously studied by our group, independent factors for the prediction of cosmetic outcome in BCS are tumour location and tumour volume to breast volume ratio. This volume ratio was obtained through 3-D visualisation of breast MRI images (10). Based on these factors a prediction model is made predicting the expected cosmetic outcome for BCS. The prediction model could aid in the treatment decision by differentiation of patients with an expected favourable cosmetic outcome and thereby improve cosmetic outcome and patients’ quality of life.
Within this randomised trial participant will undergo an additional 3-D ultrasonography of the affected breast. Ultrasonography has a broad clinical applicability in breast cancer patients and is not dependent on the use of ionizing radiation. Measurements, obtained by the Automated Breast Volume Scanner (ABVS) and 3-D ultrasonography (3-D US) have previously been compared to MRI and histopathological tumour size with good agreement [ 12, 13]. An additional validation compared volume measurements of the3-D US to those measured by histopathological and 3-D MRI. Both breast and tumour volume showed high agreement (unpublished data).
This study aims to improve cosmetic outcome following BCS by using a preoperative prediction model based on 3-D ultrasonography.


The objective of this randomized controlled trial is to compare cosmetic outcome following a standard preoperative work-up by that of the preoperative prediction model. The hypothesis is that the addition of the preoperative prediction model aids in the treatment-decision making and therefore improves cosmetic outcome and quality of life in patients opting for BCS.


Trial design

This single-blinded, multicentre, randomised controlled trial targets women with the diagnosis of primary breast cancer. Patients will randomly be assigned (1:1) to either the intervention or control group after written informed consent is given. The study is in compliance with the Helsinki declaration. Ethical approval has been granted by the Institutional Review Board of the Erasmus University Medical Centre, Rotterdam, the Netherlands (reference-number: MEC-2013-360). This trial is registered before the start of the inclusion on February 17th, 2015 (NTR 4997). Figure 1 present a flow-diagram of the trial design.


Women with pathologically confirmed primary invasive breast cancer (cT1–3) that are eligible and opt for BCS will be included. Additional inclusion and exclusion criteria are presented in Table 1.
Table 1
Inclusion and exclusion criteria
Inclusion criteria
Exclusion criteria
Recurrent breast cancer ipsilateral
Aged >18 years
Previous radiation therapy ipsilateral breast
Primary breast cancer
Pathologically proven breast cancer TI-III
Eligible for breast conserving surgery (BCS)


Volumetric measurements

All patients will receive an additional ultrasound performed by the Automated Breast Volume Scanner (ABVS– ACUSON S2000™ ABVS, Siemens Medical Solutions, Inc., Mountain View, CA) available at the department of Radiology, Erasmus MC Cancer Institute [ 14]. A standardized scanning technique is used where 3 or 5 scans are performed (i.e. anterior-posterior, lateral and medial view or anterior-posterior, upper lateral-, lower lateral-, upper medial- and lower medial-quadrant). Data from the ABVS is visualised by the ‘V-scope’ software (department of Bioinformatics, Erasmus MC) through an interactive 3-D image on the desktop system. Volume measurements are performed using a tracking system and a wireless joystick [ 15].

Prediction model

The tumour to breast volume ratio and the location of the tumour in the breast are used in the prediction model to calculate the chance of superior cosmesis in case of BCS. If the probability exceeds the predefined threshold primary BCS is advised. If the probability is below the predefined threshold an alternative treatment will be advised (i.e. oncoplastic BCS, mastectomy with or without a breast reconstruction or neo-adjuvant chemotherapy). The threshold is defined by modelling the differences in quality of life utilities between the different surgical strategies and the associated cosmetic results.

Pre-operative work-up

For all randomized patients the following characteristics will be collected (if applicable): age, body mass index (BMI), comorbidity, previous operations, smoking status, hormonal status, tumour morphology, TNM stadium, post-operative complications, radiotherapy details, chemotherapy details and hormonal therapy details.
Preoperatively all patients will be asked to complete three questionnaires. This includes the ‘Breast Q – preoperative modules’ [ 16], the ‘European Organisation of research and Treatment of Cancer quality of life questionnaire (EORTC-QLQ-C30 version 3 and EORTC-QLQ-B23 version 1)’ and ‘Euro-QoL 5D-5 L questionnaire’ (EQ-5D-5 L-version 2). All patients will preoperatively be discussed in multidisciplinary consultation. For the intervention group, the optimal treatment based on the results of the prediction model will be taken into consideration. All patients will be blinded for the result of the prediction model. Preoperative photographs will be taken by a professional medical photographer. These photographs include the 1) face-view position with the arms down, 2) face-view with arms in the side and 3) lateral view (90°) off the affected breast. The face view photographs will cover the area of chin to the umbilicus protecting the subject’s privacy and anonymity.


Three questionnaires will be obtained at all follow-up visits (i.e. ‘BREAST-Q postoperative modules’, the EORTC-QLQ-C30/B23 and the EQ-5D-5 L. Follow-up visits will be scheduled at 3 months (T1), 1 year (T2), and 3 year (T3) postoperatively. Photographs will be obtained both 1 and 3 year following BCS.


The outcome measures are summarized in Table 2.
Table 2
Assessments and used instruments with timeframe indication
Primary endpoint
 Cosmetic result
Evaluation clinical photos by panel - ‘Erasmus MC panels’ questionnaire’
Secondary outcome
 Cosmetic result/satisfaction with breast assessed by patient
Breast Q - preoperative module
Breast Q - postoperative module
 Patients’ Quality of life
EORTC QLQ-C30/B23 questionnaire
EQ-5D-5 L questionnaire
 Cosmetic result BCCT.core
BCCT.core software (INESC Porto Breast Research Group)
 Radiation-induced reaction
 Surgical strategy performed
Performed surgery/surgeries
 Pathological result
Data of pathology reports
Quality-Adjusted Life Year (QALY) for direct and indirect costs
T0 = first visit outpatient clinic, T1 = 3 months postoperative, T2 = 1 year postoperative, T3 = 3 years postoperative

Primary outcome

The cosmetic outcome evaluation will be performed by a 6-member, independent panel using the photographs. Each panel consist of 1) a plastic surgeon/breast cancer surgeon, 2) a general practitioner, a medical doctor, 3) a radiation oncologist, 4) a layperson and 5) a breast cancer survivor. Cosmetic outcome will be evaluated using a previously reported in-house developed questionnaire containing 11 aggregating previous recommendations [ 17] (see Additional file 1 A ‘Erasmus MC panels’ questionnaire’). Answers are scored on a four point Harvard cosmetic scale: 0 = ‘excellent’, 1 = ‘good’, 2 = ‘moderate’, and 3 = ‘bad’ [ 18].
Secondary outcome(s).
1) Patient reported outcome is measured by the ‘BREAST-Q’, ‘EORTC-QLQ-C30/BR23’ and ‘EQ-5D-5 L’ questionnaires (T0–3).
2) Cosmetic outcome assessed by the ‘BCCT.core software’ - INESC Porto Breast Research group [ 19] based on medical photographs (T0–2-3).
3) Radiation reaction scored by the ‘Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer’ – ‘RTOG/EORTC’ (T2–3) [ 20].
4) Surgeries performed (T3).
5) Pathological results (T3).
6) Cost-effectiveness ; direct costs will include the pre-operative care together with the costs for (surgical) treatment. Indirect costs will generally include adjuvant operation(s) if applicable and costs of outpatient clinic visits or hospitalisation (T4).

Data collection and statistical analysis

Primary study parameter

Cosmetic outcome is calculated by obtaining the mean score for all panel members. The score per panel member is based on the mean score off the 11 scored items combined. Subsequently, the mean panel evaluation will be dichotomized by defining a mean of <1.5 as superior and a mean of >1.5 as inferior. The primary outcome is the incidence of a superior cosmetic outcome in both arms. Difference will be evaluated by using the Chi-square analysis (if normally distributed) or the non-parametric Kruskal-Wallis test (if not normally distributed).

Secondary study parameters

Cosmetic result assessed by the patient (BREAST-Q), cosmetic evaluation through BCCT.core and radiation-induced reaction (RTOG/EORTC) will be analysed by comparing the intervention and control group. For normally distributed categorical data, the Chi-Square test will be used and the Kruskal Wallis test if not normally distributed. Continues variables as the Q-score will be analysed making use of the Student T-test if normally distributed or Mann-Whitney U test if not normally distributed. Pathological result will be analysed by comparing the percentages of incomplete tumour excisions and mean lumpectomy specimen size between the two study arms. The secondary study parameters will be analysed based on the intention-to-treat principle (i.e. including the patients treated with mastectomy). Surgical strategies performed will be analysed by comparing the percentages of the different types of surgery performed by using a Chi-square analysis if normally distributed or Kruskal-Wallis test if not normally distributed. Patients’ quality of life, conducted through the EORTC questionnaire/Euro-QoL and BREAST-Q questionnaires will be presented in a quantitative manner. Cost-effectiveness will be calculated by Markov modelling using ‘Quality-Adjusted Life Years’ (QALY’s).

Sample size

In our previously performed retrospective study the incidence of a superior cosmetic result, without intervention, was 71%. An improvement of superior cosmetic outcome to 85% was considered clinically relevant. Expected clinical relevant difference is a 14% improvement in the incidence of a superior cosmetic result as evaluated by an independent panel. The sample size calculation is based on comparing two proportions in independent groups by the Chi-Square test. With 80% power and 5% significance level we need a study population of 240 patients (120 in each arm). There is a possibility that even after randomization the patient can still undergo mastectomy instead of BCS. We expect this for less than 25% patients in each arm, therefore we aim to include 300 patients in total (150 in each arm).


The literature provides limited predictive factors for an expected favourable cosmetic outcome in breast cancer patients opting for BCS. To objectively device a tailor-made treatment plan this study makes use of a prediction model [ 10]. This study aims to provide level 1B evidence for the use of a preoperative prediction model for clinical decision making to improve cosmetic results in patients opting for BCS.
Following the inclusion of the first 30 patients (10%) the patients’ experiences tell us that the study is well accepted and appreciated. It is however of great importance that the study is discussed by the treating surgeon at the first or second consultation at the outpatient clinic. By the start of inclusion up to 40% of the approached patients declined participation. This was mainly based on too much burdening in the preoperative phase and an inadequate introduction of the study. If the treating surgeon introduces the study and explains the importance of the study in the preoperative phase the acceptance for participation is higher. With the allocation of multiple including centre’s in the region of Rotterdam the inclusion rate has adequately improved with an ongoing high acceptance of participating patients.
Preoperative assessment of patients’ quality of life and satisfaction with their breast is currently lacking in the literature available. Only few trials have combined postoperative cosmetic outcome measurements by panel or software with patient reported outcome measures (PROMs) [ 2123]. Especially an evaluation of cosmetic outcome through time following breast surgery is scarce [ 21]. By preoperatively collecting aesthetics and PROMs a reliable understanding of the relationship between cosmetic results and self-image or quality of life is gained. Comparing overall health-related quality of life (EORTC-QLQ-C30/B23 and EQ-5D-5 L) and treatment- or surgery specific outcomes (BREAST-Q) gives a better understanding between overall and disease-specific quality of life [ 16, 24, 25]. With this knowledge, future treatment decision making and cosmetic outcome evaluation can possibly be based on PROMs. To adequately study cosmetic outcome and their relationship to PROM’s, standardized, reproducible and easily available tools are needed [ 18, 26]. Comparing two different panel evaluations within 68 patients following BCS our group found almost perfect inter- and intra-observer agreement. Interclass correlation coefficient showed R = 0.93, R = 0.9 respectively for the inter- and intra-observer agreement [unpublished data]. When comparing trials differences in panel evaluations found are based on panel size and the use of layperson versus experts [ 23, 27, 28]. Moreover multiple and unstandardized questionnaires are used to obtain cosmetic outcome; making a comparison between different trials difficult. Based on previous recommendations of Cardoso et al. our current study uses a questionnaire concerning the different aspect of cosmetic outcome when evaluating the breast by panel members [ 17]. The BCCT.core software is known to evaluate asymmetry, skin colour difference(s) and scar features based on the situation of two identical breasts [ 2931]. In line with previous literature our group found a moderate agreement (unpublished data) between panel and BCCT core evaluation [ 22, 23]. An independent 6-member panel will therefore assess cosmetic outcome as our primary outcome. In summary this study aims to improve cosmetic outcome and quality of life through the implementation of a preoperative prediction model for breast cancer patients opting for BCS.


The authors would like to thank the INESC Porto Breast Research Group for the use of the BCCT.core software.


The study is partly externally funded through a major funding body by a non-profit foundation; ‘Stichting Theia, Zilveren Kruis Achmea’ (award number 2013204). The foundation has enabled the start and continuation of the study upon the second year of the inclusion. The foundation has no role in the data collection, data analysis, data interpretation or the writing of the manuscript. The foundation ‘Coolsingel’ has enabled the availability of the Automated Breast Volume Scanner used in the current trial to obtain an additional breast ultrasonography. The ‘Coolsingel’ has no role in the study design, data collection, data analysis, data interpretation or the writing of the manuscript.

Availability of data and materials

The datasets generated during the current study are not publicly available due to privacy regulations but are (partly) available from the corresponding author on reasonable request. During the study patient data will be stored in a Case Report Form (CRF)/repository – ‘Open Clinica’, available for the principal investigator and executing researchers.

Authors’ contributions

ML, EV, LK and WvL contributed both to the conception and design of the study. ML and EV both contributed substantially to drafting the current study protocol. The manuscript was critically revised for important intellectual content by: MH, JP, EC, CdM, CvD, JD, WV, CC, CV, WvL and LK. All authors have given their final approval of the current manuscript version and have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study is in compliance with the Helsinki declaration. Ethical approval has been granted by the Institutional Review Board of the Erasmus University Medical Centre, Rotterdam, the Netherlands (reference-number: MEC-2013-360). This trial is registered before the start of the inclusion on February 17th, 2015 (NTR 4997). Upon inclusion, prior to randomisation, a written informed consent is obtained from all participants.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Cancer 1/2017 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.